Resources | Press Releases |Press Release

Neurologix, Inc. (OTCBB:NRGX), a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced today that Marc Panoff, the company’s Chief Financial Officer, will present at the Roth Capital Partners 22nd Annual OC Growth Stock Conference. The conference will be held March 15 - 17 at The Ritz Carlton Laguna Niguel in Dana Point, CA.

Mr. Panoff will be making his presentation on March 16 at 2:00 pm Pacific Time. The presentation will be broadcast live on the internet at http://www.wsw.com/webcast/roth23/nrgx/

Founded in 1984, Roth Capital Partners, LLC is an independent investment bank dedicated to emerging growth companies in the small and micro-cap market. For more information about the conference, see http://www.roth.com/main/Page.aspx?PageID=7226.

About Neurologix

Neurologix, Inc. (OTCBB:NRGX) is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of life-altering gene transfer therapies for serious disorders of the brain and central nervous system. Neurologix's therapeutic approach is built upon the groundbreaking research of its scientific founders and advisors, whose accomplishments have formed the foundation of gene therapy for neurological illnesses. The Company's current programs address such conditions as Parkinson's disease, epilepsy and Huntington's disease, all of which are large markets not adequately served by current therapeutic options. For more information, please visit the Neurologix website at http://www.neurologix.net.